Lv5
870 积分 2024-01-29 加入
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
2小时前
求助中
P3.12.73 Phase I/II Study on WSD0922-FU in EGFR C797S+ NSCLC
14天前
已完结
Distinct expression pattern of claudin‐6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas
6个月前
已完结
Global epidemiology of epithelial ovarian cancer
7个月前
已完结
Malignant Epithelial Tumors of the Ovary
7个月前
已关闭
OA10.04 Phase II Study of Iza-Bren (BL-B01D1) Combo With Osimertinib in EGFR Mutated Locally Advanced or Metastatic NSCLC Patients
8个月前
已关闭
Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2– advanced/metastatic breast cancer in Japan: Results from the IRIS study
10个月前
已完结
Real‐World Progression‐Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real‐World Data
10个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
10个月前
已完结
皖公网安备34019202002308
